Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy
Status:
Terminated
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a larger dose of the aldosterone antagonist
spironolactone combined with a lower dose of an ACE inhibitor is more effective in reverse
left ventricular remodeling in severe congestive heart failure in patients with nonischemic
cardiomyopathy.